+Compare
KOD
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
107M

KOD Kodiak Sciences Forecast, Technical & Fundamental Analysis

a developer of novel therapies for the treatment of retinal disease

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for KOD with price predictions
08:00 PM EDT Sep 26, 2023

KOD in -6.70% downward trend, falling for three consecutive days on September 22, 2023

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where KOD declined for three days, in of 287 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for KOD entered a downward trend on September 26, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KOD's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

KOD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.304) is normal, around the industry mean (22.662). P/E Ratio (0.000) is within average values for comparable stocks, (131.532). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.103). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (306.452).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KOD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KOD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 407B. NVO holds the highest valuation in this group at 407B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 17%, and the average quarterly price growth was 37%. SYBX experienced the highest price growth at 816%, while BCLI experienced the biggest fall at -78%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 126% and the average quarterly volume growth was 75%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

KOD is expected to report earnings to fall 21.57% to -120 cents per share on November 15

Kodiak Sciences KOD Stock Earnings Reports
Q3'23
Est.
$-1.20
Q2'23
Missed
by $0.38
Q1'23
Missed
by $0.02
Q4'22
Beat
by $0.13
Q3'22
Beat
by $0.25
The last earnings report on August 14 showed earnings per share of -152 cents, missing the estimate of -114 cents. With 388.12K shares outstanding, the current market capitalization sits at 107.00M.
A.I. Advisor
published General Information

General Information

a developer of novel therapies for the treatment of retinal disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1200 Page Mill Road
Phone
+1 650 281-0850
Employees
112
Web
https://www.kodiak.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EGWCX8.570.10
+1.18%
Allspring Discovery Small Cap Gr C
LAVGX11.410.09
+0.80%
Lord Abbett International Growth R6
OAYWX19.900.14
+0.71%
Oakmark Global Select Advisor
FSPCX75.150.17
+0.23%
Fidelity® Select Insurance Port
EMGAX22.44-0.01
-0.04%
Allspring Emerging Markets Equity A

KOD and

Correlation & Price change

A.I.dvisor indicates that over the last year, KOD has been loosely correlated with VRCA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if KOD jumps, then VRCA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KOD
1D Price
Change %
KOD100%
-6.12%
VRCA - KOD
46%
Loosely correlated
-0.52%
BCDA - KOD
45%
Loosely correlated
+0.99%
STOK - KOD
41%
Loosely correlated
-3.08%
ALXO - KOD
40%
Loosely correlated
+3.99%
NTLA - KOD
38%
Loosely correlated
-1.03%
More

Groups containing KOD

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KOD
1D Price
Change %
KOD100%
-6.12%
drugs
(undefined stocks)
38%
Loosely correlated
+2.88%
biotechnology
(undefined stocks)
37%
Loosely correlated
+2.88%
treatment
(undefined stocks)
32%
Poorly correlated
-0.37%